The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / ACR/ARHP Annual Meeting 2012: Immunosuppressed Rheumatic Disease Patients Still Candidates for Vaccines

ACR/ARHP Annual Meeting 2012: Immunosuppressed Rheumatic Disease Patients Still Candidates for Vaccines

February 1, 2013 • By Thomas R. Collins

  • Tweet
  • Email
Print-Friendly Version / Save PDF

WASHINGTON, D.C.—People with rheumatic diseases should be considered for flu and pneumococcal vaccines—but generally not live vaccines—even if they are on immunosuppressive drugs, an expert said during a session titled, “Immunizations in Patients with Rheumatologic Disease,” here at the 2012 ACR/ARHP Annual Meeting, held November 9–14. [Editor’s Note: This session was recorded and is available via ACR SessionSelect at www.rheumatology.org.]

You Might Also Like
  • ACR/ARHP Annual Meeting 2012: Risk of Immunosuppression from Rheumatic Disease Therapies Poses Challenge for Rheumatologists
  • ACR/ARHP Annual Meeting 2012: New Research Delves Into the Risk of Comorbidities for Patients with Lupus
  • Tips for Treating Pain, Depression in Patients with Rheumatic Disease Offered at the ACR/ARHP’s 2013 Annual Meeting
Explore This Issue
February 2013
Also By This Author
  • The ACR’s State-of-the-Art Clinical Symposium: Stem Cell Therapy in Autoimmune Disease Evolution, Insights

But since immunosuppression can impair the response to these vaccines—and evidence suggests that methotrexate may be more to blame than antitumor necrosis factor therapies alone—getting patients vaccinated early on is the best course, said Gil Melmed, MD, MS, director of clinical trials at the Inflammatory Bowel Disease Center at Cedars-Sinai Medical Center in Los Angeles.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

“In our diseases that we treat, immunosuppression is unpredictable,” he said, referring to autoimmune disorders. “Somebody may not be on immunosuppression now, but they may require immunosuppression tomorrow. So we have them here today, let’s take advantage of the opportunity to educate them and administer the vaccines that they should get… They may actually respond less robustly tomorrow after they are on that immunosuppressive therapy.”

Taking on an Internist Role

Rheumatologists may need to assume the role of an internist, including advising patients on getting vaccines, he said. “There are many healthcare maintenance issues that we need to think about that may not necessarily be addressed appropriately by primary care providers who usually take care of healthcare maintenance,” Dr. Melmed said.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

The risk of infection in rheumatologic disease or any disease treated with immunosuppressive therapies is the most common significant adverse event that doctors have to be aware of, and many of those infections are preventable with routine vaccinations.

But patients are not getting vaccinated nearly often enough. Studies have found that only 50% to 60% of patients with rheumatic diseases on immunosuppressives are up to date on flu and pneumococcal vaccines.1,2 One recent study found that a predictor of vaccination was a rheumatologist being in practice for fewer than 10 years.1

At-risk patients are generally not getting their vaccines, even when they have had recent visits to a primary care physician.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Simply finding a spot in the practice flow for a brief questionnaire—and then immediately rerouting patients to receive a vaccine or at least vaccine education—can be effective in boosting vaccine rates, Dr. Melmed said. So can assigning a nonphysician vaccination coordinator.

Disease Activity in SLE

One study found that systemic lupus erythematosus (SLE) patients with no active disease had a similar response to healthy controls when given the H1N1 vaccine.3 However, those with active disease had a lower seroconversion rate; it was even worse for those with very active disease.

Pages: 1 2 3 4 | Single Page

Filed Under: Conditions, Meeting Reports Tagged With: Drugs, Immune System, patient care, vaccineIssue: February 2013

You Might Also Like:
  • ACR/ARHP Annual Meeting 2012: Risk of Immunosuppression from Rheumatic Disease Therapies Poses Challenge for Rheumatologists
  • ACR/ARHP Annual Meeting 2012: New Research Delves Into the Risk of Comorbidities for Patients with Lupus
  • Tips for Treating Pain, Depression in Patients with Rheumatic Disease Offered at the ACR/ARHP’s 2013 Annual Meeting
  • ACR/ARHP Annual Meeting 2012: Spondylarthritis Criteria Changing Landscape of the Disease

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)